Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo

Treatment of relapsed/resistant acute myeloid leukaemia (AML) remains a significant area of unmet patient need, the outlook for most patients remaining extremely poor. A promising approach is to augment the anti‐tumour immune response in these patients; most cancers do not activate immune effector c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rastogi, Namrata, Baker, Sarah, Man, Stephen, Uger, Robert A., Wong, Mark, Coles, Steven J., Hodges, Marie, Gilkes, Amanda F., Knapper, Steven, Darley, Richard L., Tonks, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological malignancy ‐ Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851282/
https://www.ncbi.nlm.nih.gov/pubmed/32996123
http://dx.doi.org/10.1111/bjh.17125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851282/
https://www.ncbi.nlm.nih.gov/pubmed/32996123
http://dx.doi.org/10.1111/bjh.17125

Ejemplares similares